Wintac Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Mar 2018

1. The above financial results have been reviewed by the audit committee and approved by the Board of Directors in its meeting held on 23/05/2018 and audited by the Statutory auditors of the Company.

2. The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 (transition date being April 1, 2016) and accordingly, these financial results have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder.

3.The Company recognises only one reportable business segment, viz. Formulations.

4. No Investor complaints was received during the quarter and was disposed off. No complaints were outstanding at the end of the quarter.

5. The financial results of the Company are prepared in accordance with Indian Accounting Standards (Ind AS) subsequent to adoption with the transition date of April 1, 2016 pursuant to Ministry of Company Affairs notification under Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Rules, 2016. Accordingly, these financial results have been prepared in accordance with the recognition and measurement principles in Ind AS prescribed under section 133 of the Companies Act, 2013 and SEBI Circular No. CIR/ CFD/ FAC/62/2016 dated July 5, 2016. The figures of the quarter ended and year ended March 31, 2017 prepared under earlier Indian GAAP have been restated in accordance with Ind AS.

8. In view of the advances/ support received from the major customers, the management doesn't expect any constraints in cash flow which might affect companies ability to meet its liabilities. Accordingly, despite of the Company's networth has substantially eroded, the management doesn't find any material uncertainty which may cast significant doubt on the Company's ability to continue as going concern.

9. The Manufacturing Plant was recently audited by the USFDA for a pre-approval and general GMPs and the Company has since received the E.I.R.

10. Previous period's figures have been re-grouped/rearranged/recasted wherever required in conformity with current period's presentation.